Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy.

Pigment epithelium-derived factor (PEDF) is a potent angiogenic inhibitor. Previous studies have shown that decreased ocular levels of PEDF are associated with diabetic retinopathy. However, the implication of PEDF expression in diabetic nephropathy has not been revealed. In the present study, we demonstrated for the first time that the expression of PEDF was decreased at both the mRNA and protein levels in the kidney of diabetic rats, whereas transforming growth factor-beta (TGF-beta) and fibronectin levels were increased in the same diabetic kidneys. As shown by immunohistochemistry, the decrease of PEDF expression occurs primarily in the glomeruli. In vitro studies showed that high concentrations of glucose significantly decreased PEDF secretion in primary human glomerular mesangial cells (HMCs), suggesting that hyperglycemia is a direct cause of the PEDF decrease in the kidney. Toward the function of PEDF, we showed that PEDF blocked the high-glucose-induced overexpression of TGF-beta, a major pathogenic factor in diabetic nephropathy, and fibronectin in primary HMCs, suggesting that PEDF may function as an endogenous inhibitor of TGF-beta expression and fibronectin production in glomeruli. Therefore, decreased expression of PEDF in diabetic kidneys may contribute to extracellular matrix overproduction and the development of diabetic nephropathy.

[1]  S. Okushiba,et al.  Expression of Pigment Epithelium-Derived Factor Decreases Liver Metastasis and Correlates with Favorable Prognosis for Patients with Ductal Pancreatic Adenocarcinoma , 2004, Cancer Research.

[2]  Jian-guo Ren,et al.  Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[3]  P. Campochiaro,et al.  Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. , 2004, American journal of ophthalmology.

[4]  C. Barnstable,et al.  PEDF: a multifaceted neurotrophic factor , 2003, Nature Reviews Neuroscience.

[5]  B. Kasinath,et al.  Vascular endothelial growth factor induces protein synthesis in renal epithelial cells: a potential role in diabetic nephropathy. , 2003, Kidney international.

[6]  C. Barnstable,et al.  Therapeutic prospects for PEDF: more than a promising angiogenesis inhibitor. , 2003, Trends in molecular medicine.

[7]  M. Goligorsky,et al.  Role of VEGF in Kidney Development, Microvascular Maintenance and Pathophysiology of Renal Disease , 2003, The Korean journal of internal medicine.

[8]  N. Bouck,et al.  Pigment epithelium–derived factor regulates the vasculature and mass of the prostate and pancreas , 2003, Nature Medicine.

[9]  S. Crawford,et al.  Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model. , 2003, Journal of pediatric surgery.

[10]  G. Lang,et al.  Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy , 2003, Diabetologia.

[11]  S. Hong,et al.  Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. , 2003, Biochemical and biophysical research communications.

[12]  M. Matsumura,et al.  Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. , 2002, American journal of ophthalmology.

[13]  R. Kalluri,et al.  Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. , 2002, Kidney international.

[14]  G. Gao,et al.  Down-regulation of Vascular Endothelial Growth Factor and Up-regulation of Pigment Epithelium-derived Factor , 2002, The Journal of Biological Chemistry.

[15]  M. Cooper,et al.  Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy , 2001, Diabetologia.

[16]  B. Brenner,et al.  Pathogenesis of diabetic nephropathy: focus on transforming growth factor-β and connective tissue growth factor , 2001, Current opinion in nephrology and hypertension.

[17]  P. Campochiaro,et al.  Pigment epithelium‐derived factor inhibits retinal and choroidal neovascularization , 2001, Journal of cellular physiology.

[18]  A. Hendrickson,et al.  Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissues. , 2001, Molecular vision.

[19]  Jian-xing Ma,et al.  Unbalanced expression of VEGF and PEDF in ischemia‐induced retinal neovascularization , 2001, FEBS letters.

[20]  N. Bouck,et al.  Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Greener.  Targeting TGF could counter diabetic nephropathy. , 2000, Molecular medicine today.

[22]  K. Sharma,et al.  Utility of Serum and Urinary Transforming Growth Factor-Beta Levels as Markers of Diabetic Nephropathy , 2000, Nephron.

[23]  F. Santilli,et al.  Role of Growth Factors in the Development of Diabetic Complications , 2000, Hormone Research in Paediatrics.

[24]  F. López‐Casillas.  [Transforming growth factor-beta (TGF-beta), keystone in diabetic nephropathy]. , 2000, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[25]  Hiroyuki Tanaka,et al.  Growth Hormone Therapy in Achondroplasia , 2000, Hormone Research in Paediatrics.

[26]  Matthew D. Davis,et al.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. , 2000, The New England journal of medicine.

[27]  G. Gambaro,et al.  GLUT-1 and TGF-beta: the link between hyperglycaemia and diabetic nephropathy. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  K. Forrest,et al.  Urinary measurement of transforming growth factor-beta and type IV collagen as new markers of renal injury: application in diabetic nephropathy. , 1998, Clinical chemistry.

[29]  L. Aiello,et al.  Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. , 1998, Ophthalmic research.

[30]  I. Rodriguez,et al.  Organization, evolutionary conservation, expression and unusual Alu density of the human gene for pigment epithelium-derived factor, a unique neurotrophic serpin. , 1996, Molecular vision.

[31]  A. Pfeiffer,et al.  Elevated Plasma Levels of Transforming Growth Factor-β1 in NIDDM , 1996, Diabetes Care.

[32]  D. Bok,et al.  Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[33]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[34]  J. Tombran-Tink,et al.  PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. , 1991, Experimental eye research.

[35]  S. Okuda,et al.  Role of TGF-beta in the progression of renal fibrosis. , 2003, Contributions to nephrology.

[36]  B. Weston,et al.  CTGF mediates TGF-beta-induced fibronectin matrix deposition by upregulating active alpha5beta1 integrin in human mesangial cells. , 2003, Journal of the American Society of Nephrology : JASN.

[37]  A. Krolewski,et al.  TGF-beta 1 as a genetic susceptibility locus for advanced diabetic nephropathy in type 1 diabetes mellitus: an investigation of multiple known DNA sequence variants. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  G. Gambaro,et al.  PROTEINS, GROWTH FACTORS, AND PROGRESSION OF KIDNEY DISEASE VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTORS IN DIABETIC NEPHROPATHY: EXPRESSION STUDIES IN BIOPSIES OF TYPE 2 DIABETIC PATIENTS , 2003 .

[39]  S. Okuda,et al.  Role of TGF- in the Progression of Renal Fibrosis , 2003 .

[40]  J. Ji.  Pigment epithelium derived factor:a potent inhibitor of angiogenesis , 2002 .

[41]  P. Lane,et al.  Streptozocin Diabetes Elevates all Isoforms of TGF-β in the Rat Kidney , 2001, International journal of experimental diabetes research.

[42]  G. Viberti,et al.  Pathogenesis of diabetic nephropathy. , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[43]  S. Goldfarb,et al.  TGF-beta: a crucial component of the pathogenesis of diabetic nephropathy. , 2001, Transactions of the American Clinical and Climatological Association.

[44]  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy , 2000, American journal of ophthalmology.

[45]  The Diabetes Control and Complications Trial , 1998 .

[46]  A. Pfeiffer,et al.  Elevated plasma levels of transforming growth factor-beta 1 in NIDDM. , 1996, Diabetes care.

[47]  B. Weston,et al.  J Am Soc Nephrol 14: 601–610, 2003 CTGF Mediates TGF-�–Induced Fibronectin Matrix Deposition by Upregulating Active �5�1 Integrin in Human , 2022 .